FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62135
News▲ Bullish
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 15:13 UTC
LAST UPDATE2026-10-02 15:13 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Amylin-based candidates extend the obesity-drug pipeline beyond GLP-1s, supporting long-term revenue durability for Lilly and Novo.
Next-gen obesity pipeline supports leaders
CATALYST TO WATCH
Clinical trial readouts for amylin candidates
MAIN RISK
Trial failures or safety issues derail pipeline
FULL DISPATCH
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
→CORRELATIONshares NVO, Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
→CORRELATIONshares LLY, Healthcare
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
←CORRELATIONshares LLY, NVO, Healthcare
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.